Hims & Hers Health Inc. (HIMS) saw its stock surge 5.09% in pre-market trading on Monday, following reports of soaring demand for alternative versions of the popular weight-loss drug Wegovy.

According to an industry group, more than 200,000 prescriptions for compounded copies of Wegovy are being filled each month in the U.S., with patients turning to these alternatives due to shortages and high costs of the branded drug. Hims & Hers is among the telehealth providers offering these compounded versions of Wegovy.

The surge in demand for Wegovy alternatives comes as the FDA weighs whether to remove the drug from its shortage list, which has allowed compounding pharmacies to produce and sell their own versions. If removed from the list, these pharmacies may be forced to halt production, potentially driving more patients to seek out alternatives like those offered by Hims & Hers.